Last reviewed · How we verify
NCT05547282: FL001
Low-dose Radiotherapy Combined With Conventional Radiotherapy After Immunotherapy Failure
NA trial testing At the same time, the original regimen of immunomaintenance therapy was continued, according to the frequency of the original immunization regimen once every 3 weeks until progress. in Cancer Patients in 20 participants. Status unknown.
1 February 2024
Quick facts
| Lead sponsor | Jiandong Zhang |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 October 2022 |
| Primary completion | 1 February 2024 |
| Estimated completion | 1 February 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- At the same time, the original regimen of immunomaintenance therapy was continued, according to the frequency of the original immunization regimen once every 3 weeks until progress.
Conditions studied
- Cancer Patients — all drugs for Cancer Patients →
Sponsor
Jiandong Zhang
Who can join
Adults 18 to 65, any sex, with Cancer Patients. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Response was evaluated according to the Guidelines for Response Criteria for Use in Trials Testing Immunotherapeutics (iRECIST) : ORR-To evaluate the objective effective rate of LDRT combined with SFRT and immunotherapy in patients with malignant tumors after immunotherapy resistance without standard regimens. PFS-To evaluate the progression-free survival (PFS) of patients with advanced malignant tumors after LDRT combined with SFRT and immunotherapy without standard regimens after immunotherapy resistance.DCR-To evaluate the proportion of patients with optimal response to LDRT and SFRT combined with immunotherapy to achieve complete response, partial response, or disease control after no standard regimen was available for immunotherapy resistance.HRQoL, AE and sAE-Evaluation of health related quality of life and safety of post-LDRT combined with SFRT and immunotherapy in patients with malignant tumors. To evaluate the benefit of patients in this trial.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Using triple radio-immunotherapy to overcome cancer immunotherapy resistance.
Zhang Z, Zhang X, Chen D. · · 2023 · cited 1× · PMID 37975213 · DOI 10.20892/j.issn.2095-3941.2023.0268
Verify or expand the search:
- PubMed search for NCT05547282
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer Patients
Currently open trials in the same condition.
- NCT06864481 — Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis · recruiting
- NCT06889987 — Bilateral Ultrasound Guided Intramuscular Quadratus Lumborum Plane Block Versus Bilateral Lateral Quadratus Lumborum Pla · NA · recruiting
- NCT06348940 — Effects of Behavioral Activation on Negative Emotions, Cancer-related Symptoms and Clinical Indicators in Cancer Patient · NA · active not recruiting
- NCT04802720 — A Study Comparing Two Types of Supportive Interventions for Caregivers of Patients With Cancer · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05547282 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiandong Zhang
- Last refreshed: 21 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05547282.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing